$0.9668
0.055.64%
At close: -
$0.9668
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
RAPT Therapeutics Analyst Ratings and Price Targets | NASDAQ:RAPT | Benzinga
RAPT Therapeutics Inc has a consensus price target of $23.09 based on the ratings of 16 analysts. The high is $48 issued by Capital One on September 21, 2022. The low is $2 issued by UBS on September 9, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Wells Fargo on March 10, 2025, December 26, 2024, and November 12, 2024, respectively. With an average price target of $8 between HC Wainwright & Co., HC Wainwright & Co., and Wells Fargo, there's an implied 727.47% upside for RAPT Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wells Fargo
UBS
Barclays
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for RAPT Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/10/2025 | Buy Now | 934.34% | HC Wainwright & Co. | Raghuram Selvaraju43% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 12/26/2024 | Buy Now | 934.34% | HC Wainwright & Co. | Raghuram Selvaraju43% | $10 → $10 | Upgrade | Neutral → Buy | Get Alert |
| 11/25/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju43% | — | Reiterates | → Neutral | Get Alert |
| 11/12/2024 | Buy Now | 313.74% | Wells Fargo | Yanan Zhu39% | $17 → $4 | Maintains | Overweight | Get Alert |
| 11/12/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju43% | — | Reiterates | → Neutral | Get Alert |
| 11/11/2024 | Buy Now | — | JP Morgan | Anupam Rama59% | — | Downgrade | Neutral → Underweight | Get Alert |
| 09/09/2024 | Buy Now | 106.87% | UBS | Eliana Merle47% | $10 → $2 | Maintains | Neutral | Get Alert |
| 08/20/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju43% | — | Reiterates | → Neutral | Get Alert |
| 07/23/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju43% | — | Reiterates | → Neutral | Get Alert |
| 05/14/2024 | Buy Now | — | Wolfe Research | Andy Chen43% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 05/10/2024 | Buy Now | 313.74% | Barclays | Leon Wang66% | $13 → $4 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 05/10/2024 | Buy Now | — | Guggenheim | Yatin Suneja50% | — | Downgrade | Buy → Neutral | Get Alert |
| 04/10/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju43% | — | Reiterates | → Neutral | Get Alert |
| 03/27/2024 | Buy Now | 1244.64% | JP Morgan | Anupam Rama59% | $15 → $13 | Maintains | Neutral | Get Alert |
| 02/22/2024 | Buy Now | 934.34% | UBS | Eliana Merle47% | $61 → $10 | Downgrade | Buy → Neutral | Get Alert |
| 02/21/2024 | Buy Now | 1244.64% | Barclays | Leon Wang66% | $35 → $13 | Maintains | Overweight | Get Alert |
| 02/21/2024 | Buy Now | 934.34% | Leerink Partners | Thomas Smith33% | → $10 | Downgrade | Outperform → Market Perform | Get Alert |
| 02/21/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju43% | — | Downgrade | Buy → Neutral | Get Alert |
| 02/21/2024 | Buy Now | 1451.51% | JP Morgan | Anupam Rama59% | $35 → $15 | Downgrade | Overweight → Neutral | Get Alert |
| 02/20/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal40% | — | Downgrade | Overweight → Neutral | Get Alert |
| 02/16/2024 | Buy Now | — | Evercore ISI Group | Umer Raffat43% | — | Initiates | → Outperform | Get Alert |
| 02/15/2024 | Buy Now | 3933.93% | Wolfe Research | Andy Chen43% | → $39 | Initiates | → Outperform | Get Alert |
| 11/30/2023 | Buy Now | 3520.19% | JP Morgan | Anupam Rama59% | $32 → $35 | Maintains | Overweight | Get Alert |
| 11/15/2023 | Buy Now | 4140.79% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $41 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | 3416.76% | Berenberg | Andy Chen43% | → $34 | Initiates | → Buy | Get Alert |
| 08/16/2023 | Buy Now | 3209.89% | JP Morgan | Anupam Rama59% | $39 → $32 | Maintains | Overweight | Get Alert |
| 08/14/2023 | Buy Now | 3106.45% | Piper Sandler | Edward Tenthoff52% | $28 → $31 | Maintains | Overweight | Get Alert |
| 08/14/2023 | Buy Now | 4140.79% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $41 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 4037.36% | Stifel | Alex Thompson43% | → $40 | Initiates | → Buy | Get Alert |
| 06/15/2023 | Buy Now | 3520.19% | Barclays | Leon Wang66% | → $35 | Initiates | → Overweight | Get Alert |
| 06/05/2023 | Buy Now | 4140.79% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $41 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 4140.79% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $41 | Maintains | Buy | Get Alert |
| 03/30/2023 | Buy Now | 4347.66% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $43 | Reiterates | → Buy | Get Alert |
| 03/21/2023 | Buy Now | 4244.23% | JP Morgan | Anupam Rama59% | $48 → $42 | Maintains | Overweight | Get Alert |
| 03/21/2023 | Buy Now | 4347.66% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $43 | Reiterates | → Buy | Get Alert |
| 03/15/2023 | Buy Now | 4864.83% | Guggenheim | Yatin Suneja50% | $55 → $48 | Maintains | Buy | Get Alert |
| 03/15/2023 | Buy Now | 2278.98% | Goldman Sachs | Corinne Jenkins48% | $27 → $23 | Maintains | Buy | Get Alert |
| 03/15/2023 | Buy Now | 4347.66% | HC Wainwright & Co. | Raghuram Selvaraju43% | $50 → $43 | Maintains | Buy | Get Alert |
| 01/04/2023 | Buy Now | 5588.87% | Guggenheim | Yatin Suneja50% | → $55 | Initiates | → Buy | Get Alert |
| 01/04/2023 | Buy Now | 4864.83% | Wells Fargo | Yanan Zhu39% | $55 → $48 | Maintains | Overweight | Get Alert |
| 12/01/2022 | Buy Now | 2692.72% | Goldman Sachs | Corinne Jenkins48% | → $27 | Initiates | → Buy | Get Alert |
| 11/14/2022 | Buy Now | 5071.7% | HC Wainwright & Co. | Raghuram Selvaraju43% | $53 → $50 | Maintains | Buy | Get Alert |
| 11/11/2022 | Buy Now | 3416.76% | Piper Sandler | Edward Tenthoff52% | $30 → $34 | Maintains | Overweight | Get Alert |
| 09/21/2022 | Buy Now | 4864.83% | Capital One | Zegbeh Jallah65% | → $48 | Initiates | → Overweight | Get Alert |
| 08/12/2022 | Buy Now | 5382% | HC Wainwright & Co. | Raghuram Selvaraju43% | $50 → $53 | Maintains | Buy | Get Alert |
| 08/11/2022 | Buy Now | 4864.83% | SVB Leerink | Mike Kratky64% | $49 → $48 | Maintains | Outperform | Get Alert |
| 06/23/2022 | Buy Now | 5071.7% | HC Wainwright & Co. | Raghuram Selvaraju43% | $56 → $50 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | 4451.1% | Cantor Fitzgerald | Prakhar Agrawal40% | → $44 | Assumes | → Overweight | Get Alert |
| 05/12/2022 | Buy Now | 3003.02% | Piper Sandler | Edward Tenthoff52% | $52 → $30 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for RAPT Therapeutics (RAPT) stock?
The latest price target for RAPT Therapeutics (NASDAQ:RAPT) was reported by HC Wainwright & Co. on March 10, 2025. The analyst firm set a price target for $10.00 expecting RAPT to rise to within 12 months (a possible 934.34% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for RAPT Therapeutics (RAPT)?
The latest analyst rating for RAPT Therapeutics (NASDAQ:RAPT) was provided by HC Wainwright & Co., and RAPT Therapeutics reiterated their buy rating.
When was the last upgrade for RAPT Therapeutics (RAPT)?
The last upgrade for RAPT Therapeutics Inc happened on December 26, 2024 when HC Wainwright & Co. raised their price target to $10. HC Wainwright & Co. previously had a neutral for RAPT Therapeutics Inc.
When was the last downgrade for RAPT Therapeutics (RAPT)?
The last downgrade for RAPT Therapeutics Inc happened on November 11, 2024 when JP Morgan changed their price target from N/A to N/A for RAPT Therapeutics Inc.
When is the next analyst rating going to be posted or updated for RAPT Therapeutics (RAPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RAPT Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RAPT Therapeutics was filed on March 10, 2025 so you should expect the next rating to be made available sometime around March 10, 2026.
Is the Analyst Rating RAPT Therapeutics (RAPT) correct?
While ratings are subjective and will change, the latest RAPT Therapeutics (RAPT) rating was a reiterated with a price target of $10.00 to $10.00. The current price RAPT Therapeutics (RAPT) is trading at is $0.97, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
